STAAR Surgical Company stocks have been trading up by 20.26 percent following highly positive market sentiment and outlook.
Live Update At 17:03:21 EDT: On Wednesday, May 13, 2026 STAAR Surgical Company stock [NASDAQ: STAA] is trending up by 20.26%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
STAA has been climbing steadily in recent sessions. From 2026/04/20 to 2026/05/13, STAAR Surgical moved from about $25.53 to a $29.40 close, with intraday action later spiking into the mid‑$30s. That is a clear shift in momentum, and traders are paying attention.
Under the hood, STAAR Surgical is still a turnaround story. The latest quarterly report shows revenue of about $57.8M, but operating income came in around -$56.7M, and net income was roughly -$18.3M. Despite those losses, STAA sports a fat 76.2% gross margin, which tells traders the core implantable lens product line has strong pricing power. The problem is overhead and growth spending, not demand.
Cash is a bright spot. STAA holds roughly $153.2M in cash and $187.5M in cash and short‑term investments, with total debt modest at about $32.5M. A current ratio of 4.6 and quick ratio of 3.5 signal plenty of liquidity. That balance sheet gives STAAR Surgical time to fix profitability while still funding research, sales, and global expansion.
Why Traders Are Watching STAA Into Earnings
The catalyst is clear. STAAR Surgical just told the market it will drop Q1 2026 numbers and a shareholder letter on 2026/05/13, followed by an earnings call. For active traders, that is a date to circle in red. Earnings plus a focused management call often reset expectations, and STAA has the kind of chart and fundamentals that can fuel sharp moves in either direction.
On the daily chart, STAA has been in a short near‑term uptrend. The stock pushed from the mid‑$24s in late April to the high‑$20s by 2026/05/13. Intraday data shows an even more aggressive late‑day squeeze, with STAA running from a regular‑session close at $29.40 to over $34 in extended trading. That kind of jump tells you there is real positioning happening ahead of the Q1 2026 release.
Why so much focus now? Because STAAR Surgical is at an inflection point. The company is losing money, but it has elite gross margins, low debt, and a big cash cushion. Traders know that if management lays out a credible path to scale sales and control costs, sentiment can flip fast. If the call instead signals more heavy spending and delayed profitability, momentum traders will react just as quickly the other way.
China adds another twist. STAAR Surgical specifically highlighted China as a key topic for the earnings call. That raises questions on demand trends, pricing, and regulatory dynamics in one of the most important vision‑correction markets in the world. Any new color on China growth could become the headline driver for STAA’s next major move.
More Breaking News
- RCAT Stock Slides As Massive Equity Offering Hits Tape
- POET Technologies Whipsaws As New COO And 2x ETF Stoke Volatility
- CLIK Stock Slides After Extreme Pre-Market Spike
- AAOI Stock Whipsaws As Analysts Hike Price Targets On AI Hopes
Conclusion
For active traders, STAA is lining up as a classic catalyst setup. You have a stock that has quietly pushed higher for weeks, a company with strong product economics but weak bottom‑line results, and a defined event on 2026/05/13 when new data finally hits. STAAR Surgical has already shown it can move 10%+ in a blink once volume pours in; the extended‑hours ramp over $34 is proof.
The key now is preparation, not prediction. Study how STAA has reacted to past earnings. Map out key price levels from the recent range between $25 and $35. Understand the fundamentals: high gross margin, negative earnings, big cash pile, and the strategic weight of China in the growth story. When the Q1 2026 numbers and the shareholder letter drop, traders who have done that homework will be faster to react than those chasing the headline.
As Tim Sykes likes to say, “Preparation meets opportunity in the most volatile stocks.” As millionaire penny stock trader and teacher Tim Sykes, says, “Consistency is key in trading; don’t let emotions dictate your trades.”. STAA fits that playbook right now. STAAR Surgical is not a safe, sleepy name; it is a developing story where each earnings call can change the narrative. Treat the upcoming Q1 2026 release and China commentary as a trading lesson in real time, and remember this content is for educational and research purposes only, not trading advice.
This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.
Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:
- Penny Stocks Trading Guide
- Best Penny Stocks Under $1 to Buy Today
- Top 8 Penny Stocks to Watch on Robinhood
Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:
Leave a reply